Drug Commissioner of the MHH
Prof. Dr. med. Dirk O. Stichtenoth is the MHH's Drug Commissioner.
Prof. Dr. med. Dirk O. Stichtenoth advises the Presidium on all QM tasks in the area of responsibility "Drug Safety - Drug Therapy Safety (AMTS)". There is close interdisciplinary cooperation with Clinical Departments from the MHH and authorized practices in the diagnosis and treatment of patients. The office of the Drug Safety Officer requires a high degree of independence and neutrality, as this is the only way to ensure a professional medical assessment according to the criteria of evidence-based medicine.
Prof. Dr. med. Dirk O. Stichtenoth
Director
Institute of Clinical Pharmacology
Hannover Medical School
Drug Commissioner of the MHH
The Pharmaceutical Advisory Board
The Pharmaceutical Advisory Board is the Drug Commission of the MHH.
Members are the senior physicians and nursing staff of the disciplines represented at the MHH, the representatives of the Institutes of Clinical Chemistry, Microbiology, Toxicology, Clinical Pharmacology and the Central Pharmacy.
The Pharmaceutical Advisory Board is chaired by Dr. rer. biol. hum. Heike Alz, Central Pharmacy of the MHH, is Managing Director of the Pharmaceutical Advisory Board.
Tasks
As an independent body, the Pharmaceutical Advisory Board ensures optimum safety, efficacy and quality in drug therapy, taking into account economic and ecological aspects. The aim is to prevent drug-related risks and ensure responsible, evidence-based handling of drugs at all levels of the medication process.
The Pharmaceutical Advisory Board makes recommendations on the use of medicines and determines which medicines are available as standard in the Clinical Department through the hospital pharmacy and can be routinely prescribed. The MHH Pharmaceutical Advisory Board list (MHH SharePoint!) is updated after each Pharmaceutical Advisory Board meeting. Guidelines for safe and economical drug therapy for specific clinical pictures are developed together with clinical and clinical-theoretical departments.
Further information and forms for the Pharmaceutical Advisory Board can be found in MHH-SharePoint!
Application
The Pharmaceutical Advisory Board usually meets three times a year. Applications for the "Listing (MHH-SharePoint!) of certain drugs are submitted to the Drug Commissioner. An application must be submitted to the Medicines Officer two weeks before the next meeting. The decision is made on the basis of the results of clinical studies of high methodological quality.
Transparency and independence
The Medicines Commissioner publishes his potential conflicts of interest annually at the first Advisory Board meeting. Since 2007, it has been mandatory for members of the Pharmaceutical Advisory Board and applicants to disclose conflicts of interest to the Medicines Commissioner. The information is treated confidentially.